Leiner & loratadine
This article was originally published in The Tan Sheet
Executive Summary
Company's "goal is to create marketing programs to enable [its loratadine] retail private label sales to exceed 30% of the market," which it anticipates "to be $500 mil.," firm says. Leiner expects to ship its generic version of Schering-Plough's OTC Claritin in mid-July (1"The Tan Sheet" Feb. 10, 2002, p. 8). Company notes it will support initial loratadine offering by conducting "in-store promotions and regional advertising in conjunction with [its] retail consumers." Leiner will consider manufacturing, marketing other forms of loratadine at a later date, firm adds, noting that, overall, it expects "to introduce into the market new innovative products...that will generate $100 mil. in gross sales" in 2003...
You may also be interested in...
Leiner Store Brand Loratadine To Begin Retail Shipments In July
Leiner Health Products plans to begin shipping private label OTC loratadine immediate-release 10 mg tablets "on or around" July 21, according to the firm
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.